Sanara MedTech Inc. SMTI R2KPHARMA
Company Overview
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Why Investors Should Care
Revenue has grown at a 31.6% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $103.12M (+19.0% YoY); net profit $-37.56M.
- Trailing 12 Months Year-on-year growth — revenue +18.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.59% |
| 1 Year: | 18.60% |
Stock Price Performance
| 1 Year: | +8.80% |
| 6 Months: | +84.05% |
| 3 Months: | +54.77% |
| 1 Month: | +1.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)76.69 · Overbought
P/E of 578.83 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 31.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 578.8.
- RSI at 77 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SMTI Sanara MedTech Inc. R2KPHARMA | 34.73 | 578.83 | $319.28M | 0.00% | 13.45% | 2.86% | 31.59% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.01M | 6.28M | 5.82M | 7.81M | 9.67M | 13.04M | 15.52M | 15.75M | 16.02M | 18.54M | 20.16M | 21.67M | 23.43M | 25.83M | 26.33M | 27.80M |
| Gross Profit | 159.63K | 186.00K | 234.02K | 513.57K | 274.90K | 443.95K | 796.90K | 539.77K | 708.50K | 904.58K | 1.05M | 1.20M | 1.43M | 1.29M | 1.32M | 1.75M | 2.10M | 1.45M | 2.20M | 2.68M | 2.62M | 3.19M | 2.62M | 3.86M | 4.54M | 5.74M | 5.31M | 7.01M | 8.71M | 10.82M | 13.40M | 13.57M | 14.27M | 16.65M | 18.15M | 19.68M | 21.60M | 23.89M | 24.46M | 25.87M |
| Operating Income | - | - | - | - | - | - | -96.03K | -343.19K | -131.91K | 138.87K | -903.80K | 216.15K | 58.26K | 118.72K | -28.77K | 66.71K | 30.98K | -132.00K | -157.15K | -323.13K | -797.22K | -1.80M | -1.08M | -1.31M | -1.08M | -1.03M | -1.85M | -2.78M | -3.38M | -3.23M | -1.22M | -1.87M | -906.65K | -1.53M | -2.88M | 778.54K | 825.53K | -31.35K | 2.94M | 2.65M |
| Net Income | -942.27K | -32.34K | -1.69M | -596.08K | -835.84K | -735.74K | -196.87K | -646.50K | -178.71K | 90.28K | -922.44K | 181.49K | 53.06K | 79.04K | -48.56K | 6.21K | 31.17K | -151.03K | -162.57K | -351.42K | -836.98K | -1.84M | -1.13M | -1.21M | -1.18M | -1.21M | -2.05M | -3.13M | 769.43K | -1.47M | -1.18M | -1.83M | -1.06M | -1.76M | -3.50M | -2.86M | -3.53M | -2.01M | -30.41M | 458.96K |
| Diluted EPS | - | - | - | - | - | - | - | - | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.08 | 0.01 | 0.00 | -0.39 | -0.15 | -0.35 | -0.39 | -0.18 | -0.18 | - | - | - | - | 0.09 | -0.18 | -0.14 | -0.22 | -0.13 | -0.21 | -0.41 | -0.34 | -0.41 | -0.23 | -3.40 | 0.05 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.39K | 41.52K | 11.02K | 118.21K | 103.98K | 35.67K | 204.64K | 1.07M | 1.06M | 1.32M | 1.18M | 986.45K | 946.30K | 985.65K | 783.84K | 950.36K | 1.26M | 1.03M | 759.59K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.21M | 1.17M | 1.73M | 2.63M | 3.37M | 5.51M | 6.30M | 5.84M | 11.77M | 15.59M | 24.14M | 45.84M | 64.99M | 86.67M | 103.12M |
| Gross Profit | 1.41M | 375.01K | 933.62K | 1.83M | 2.48M | 4.56M | 5.50M | 5.33M | 10.56M | 13.97M | 21.83M | 39.48M | 57.14M | 78.53M | 95.60M |
| Operating Income | - | - | - | - | -964.98K | -272.13K | 120.44K | -501.86K | -2.74M | -5.03M | -7.38M | -12.52M | -4.22M | 1.26M | 7.30M |
| Net Income | -12.74M | -1.85M | -4.15M | -2.28M | -1.34M | -415.75K | 331.31K | -600.57K | -2.81M | -4.45M | -7.92M | -7.94M | -4.30M | -9.66M | -37.56M |
| Diluted EPS | - | - | - | - | - | -0.01 | 0.00 | 0.00 | -1.32 | -0.76 | - | -1.00 | -0.52 | -1.14 | -4.36 |
| R&D Expense | - | - | - | - | - | - | - | - | - | 40.19K | 558.70K | 3.37M | 4.13M | 2.83M | 5.07M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.83M | 1.39M | 977.15K | 1.50M | 1.39M | 2.17M | 2.22M | 1.71M | 11.12M | 9.83M | 36.40M | 61.04M | 73.87M | 88.09M | 72.94M |
| Total Equity | - | -3.86M | -3.81M | -2.47M | -825.40K | -1.27M | -423.07K | 102.54K | 586.80K | 6.61M | 6.15M | 30.64M | 41.83M | 44.83M | 39.40M | 5.94M |
| Cash & Equivalents | 50.84K | 3.61K | 45.86K | 44.55K | 523.44K | 182.34K | 833.48K | 463.19K | 176.42K | 6.61M | 455.37K | 18.65M | 8.96M | 5.15M | 15.88M | 16.58M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.11M | 30.69M | 45.97M |
| Total Liabilities | - | 7.69M | 5.20M | 3.45M | 2.32M | 2.66M | 2.59M | 2.12M | 1.12M | 4.72M | 3.99M | 6.24M | 19.32M | 29.28M | 49.18M | 67.01M |
| Current Liabilities | - | 6.88M | 5.01M | 3.45M | 2.32M | 1.46M | 1.39M | 2.12M | 1.12M | 2.64M | 3.54M | 6.02M | 12.81M | 13.77M | 15.29M | 18.63M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -343.60K | -1.23M | -1.82M | -1.69M | -1.20M | 409.25K | -139.86K | 277.14K | -2.17M | -4.03M | -4.81M | -5.55M | -3.25M | -23.78K | 6.79M |
| Investing Cash Flow | -1.34M | 371.84K | -29.89K | -8.45K | -5.33K | -3.03K | -85.88K | -8.48K | -1.20M | -2.74M | -5.28M | -3.51M | -10.21M | -6.61M | -14.97M |
| Financing Cash Flow | 1.63M | 896.60K | 1.85M | 2.17M | 867.12K | 244.93K | -144.55K | 0 | 9.80M | 622.33K | 28.30M | -627.35K | 9.64M | 17.37M | 8.89M |
| Capital Expenditure | - | - | -29.89K | -8.07K | -5.33K | -3.03K | -43.90K | -8.48K | -182.82K | -544.37K | -171.87K | -147.01K | -265.25K | -205.85K | -4.63M |
| Free Cash Flow | - | - | -1.85M | -1.69M | -1.21M | 406.22K | -183.76K | 268.66K | -2.35M | -4.58M | -4.99M | -5.70M | -3.51M | -229.63K | 2.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 63.8% | 32.0% | 54.1% | 69.5% | 73.5% | 82.9% | 87.2% | 91.3% | 89.7% | 89.6% | 90.4% | 86.1% | 87.9% | 90.6% | 92.7% |
| Operating Margin % | - | - | - | - | -28.6% | -4.9% | 1.9% | -8.6% | -23.3% | -32.3% | -30.6% | -27.3% | -6.5% | 1.5% | 7.1% |
| Net Margin % | -576.6% | -157.2% | -240.3% | -86.5% | -39.8% | -7.5% | 5.3% | -10.3% | -23.9% | -28.5% | -32.8% | -17.3% | -6.6% | -11.2% | -36.4% |
| ROE % | 330.1% | 48.5% | 168.0% | 276.0% | 105.4% | 98.3% | 323.1% | -102.3% | -42.5% | -72.3% | -25.9% | -19.0% | -9.6% | -24.5% | -632.5% |
| ROCE % | - | - | - | - | 1,433.9% | -35.0% | 117.5% | -85.5% | -32.3% | -80.1% | -24.3% | -26.0% | -7.0% | 1.7% | 13.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 3.97% | 248.83K | $8.60M |
| 2 | Vanguard Capital Management LLC | 3.11% | 194.90K | $6.74M |
| 3 | Royal Bank of Canada | 2.09% | 131.00K | $4.53M |
| 4 | Stonebridge Wealth Management, LLC | 2.07% | 129.45K | $4.48M |
| 5 | AQR Capital Management, LLC | 1.79% | 112.21K | $3.88M |
| 6 | Geode Capital Management, LLC | 1.42% | 89.18K | $3.08M |
| 7 | Goldman Sachs Group Inc | 1.18% | 74.20K | $2.57M |
| 8 | Renaissance Technologies, LLC | 1.08% | 67.40K | $2.33M |
| 9 | State Street Corporation | 1.01% | 63.47K | $2.19M |
| 10 | Squarepoint Ops LLC | 0.86% | 53.81K | $1.86M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SMTI
Sanara MedTech (SMTI) Stock Gets Fair Value Bump As Analysts Back Wound Care Growth - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOMk8zVmJwMEtaMERFWUhlWW1NMXVWaTZib0lDMC1jV01XY3IwTGRtMGZsaFBJV3E2bXJmYlVNOG1wSGhla2NldTAwZUhQaE1VZFNGcmlrcEhXNmZEem9HeUN1aFdtVVNUY0VWRlZuZmxJY2xWakI0M3FTTDRtanpWaXdhLTNHeDktdk80Uk…
Sanara MedTech Seeks Shareholder Approval for Merger With MiMedx - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxONW5NdWZmZHlrczhCQlhMOW5mRmZndlp2LXdockxMU1N0aTJkajVWWWNYclV3Q0NLMEk5ZE5EZHpuNEJhTnJ1WG1RRVdsNE1mV3JHYjcyS0stQ0pnUmNCdWNYYXhoOTl0blllMF9QbkpzV2JZdGxJZTVfNVdTX0ZxVXBCWjExWkxwVnZ4Wn…
SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxQckItbnJRMFpFWjlzclZuaUlsMUJrUnBZVTJnQmFlYWZLand3a25vRHQ5cjdnU3VZZ3Y0NDh0eEtZbmk1emUtMDd5dFJqcHNGYTVzSmN0TkxSWFlNbXJyM0dKTFZNXy16YmJWdlNLbDF4UEQtdGZ4WFBwSnNsVUFfUWEtTXlERDRMYlAwaz…
[DEFM14A] Sanara MedTech Inc. Merger Proxy Statement - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOTU1ZY2trYXU4UGpQcVM4dHgtVU5GQ0dkN3RQNFB4dW84Qy1yQ2Y4TjZWQ1QxQUc5Y0E5YmhoRUxid0kzT3NGaTlvZWNjNWlsSGc0aTBTcnNSV211cDhPWDR2SW9OU0FQcGswX0RDRDI2X0RBbGZkRTNvNzlsZVJRTEM5Q0kxNUZsdmdILV…
SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanar - The National Law Review
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQcW5uU01WcTY5VnJ3N1R6MDhRQVAzSjFqQS1TY3JPWTA2UlF2SkdTcURLLWhHeEtpampsb2E0bEx6bTdlWmZ6V0l4cWtjWUM3dmlYemNvZlVCekxYa1JCV19XcXBpUXFhTlVHR3lPWDdPVjg0WE1tQ3p3OGxNM0h6Q01MVTk3aU1wZW9VeV…
Sanara MedTech (SMTI) Stock Stays Quiet As Profitability Meets Debt Scrutiny - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE5QUVdHR1l3ODF1UmhuWHhodmwtS3FNWGs1LUdzSmlpU0tqdnlUamxJaHh0LTFqSl9Qa3RHM0FaaXZVdUNYdnk0UG12VFh6SjhrVHp1YUMtQVY?oc=5" target="_blank">Sanara MedTech (SMTI) Stock Stays Quiet As Profi…
SMTI — Frequently Asked Questions
What is the current share price of Sanara MedTech Inc. (SMTI)?
As of 2026-09-07 16:24 PDT, Sanara MedTech Inc. (SMTI) trades at $34.73 on NasdaqCM. Its 52-week range is $16.34 to $35.75.
What is the market capitalisation of SMTI?
Sanara MedTech Inc. (SMTI) has a market capitalisation of $319.28M on NasdaqCM.
What is the P/E ratio of SMTI?
SMTI trades at a trailing price-to-earnings (P/E) ratio of 578.83. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 44.46.
What is the return on equity (ROE) of SMTI?
SMTI has a return on equity (ROE) of 2.86%. Its return on capital employed (ROCE) is 13.45%.
Is SMTI a good stock to buy?
This page provides a data-driven analysis of Sanara MedTech Inc. (SMTI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.